a-synuclein 
Introduction
Parkinson's disease (PD) is a major neurodegenerative disorder that affects 1e2% of the population over 60 years of age. PD causes profound motor impairments including tremors at rest, rigidity, bradykinesia, and postural instability along with non-motor symptoms such as autonomic, cognitive and psychiatric problems (Olanow et al., 2009; Schapira and Olanow, 2004) . PD is a multifactorial disease that includes, but is not limited to, oxidative stress, mitochondrial dysfunction, inflammation and aberrant protein aggregation (Dawson and Dawson, 2003; Dunnett and Bjorklund, 1999) . Higher level of iron in the nigral area in early stages of PD progression has been reported in numerous publications (Belaidi and Bush, 2016; Gerlach et al., 2006; Oakley et al., 2007) , and has also been confirmed by magnetic resonance imaging (Gorell et al., 1995) and ultrasound studies (Berg, 2009 ). The proposed pathogenic mechanisms for iron-mediated neuronal degeneration involve increased oxidative stress, owing to the interaction between intracellular ferrous iron and hydrogen peroxide (H 2 O 2 ) in the Fenton reaction to generate hydroxyl free radicals (Zecca et al., 2004) , and may also cause aggregation of asynuclein (a-Syn) protein to form toxic oligomers (Bharathi et al., 2007; Ostrerova-Golts et al., 2000) . The aggregation of a-Syn protein has been linked to the pathogenesis of PD and Dementia with Lewy bodies (DLB) (Olanow and Tatton, 1999; Spillantini et al., 1997) . In addition, iron and other metals have been implicated in aggregation of a-Syn (Danzer et al., 2009; Finkelstein et al., 2016; Lei et al., 2015; Uversky et al., 2001 ). Metals, especially iron, cause fibrilization of a-Syn either via disruption of the interaction between the Ne and C-terminal regions of a-Syn or by metal-catalyzed oxidation (MCO) of a-Syn (Cole, 2008) . In a recent experiment, an iron chelator compound, clioquinol, has been shown to be effective in improving cognitive and motor function in a-Syn transgenic mice (Finkelstein et al., 2016) . Therefore, the critical cross talk between iron accumulation, a-Syn aggregation and neurodegeneration suggests that iron chelation is an attractive therapeutic strategy for potential use against PD progression (Li et al., 2011) .
The first pharmacological treatment for PD, L-dopa, when given with a peripheral dopamine (DA) decarboxylase inhibitor, dramatically improves the symptoms of the disease by producing DA in DA-depleted neurons (Birkmayer and Hornykiewicz, 2001; Cotzias et al., 1969) . However, long-term use of L-dopa gives rise to motor fluctuations with dyskinesias and a decrease in duration of response to a given L-dopa dose (Marsden and Parkes, 1976) . Importantly, L-dopa alleviates only the symptoms without affecting the course of disease progression (Schapira et al., 2005) . As of now, no neuroprotective drugs have been identified or approved by the FDA for the treatment of PD. The overall goal of our research is to develop orally active multifunctional treatment agents to address both symptomatic (relieving motor dysfunction) and diseasemodifying neuroprotective effects to slow or stop the progression of the disease (Das et al., 2015; Ghosh et al., 2010; Li et al., 2010; Modi et al., 2014; Santra et al., 2013; Shah et al., 2014) . A number of iron chelators have been employed in the preclinical and clinical studies of PD (Devos et al., 2014; Grolez et al., 2015) . One such chelator, deferiprone, has shown promising results in a recently completed 12-month clinical trial in early-stage PD patients (Devos et al., 2014) , indicating the potential application of suitable iron chelators in disease modification. Additionally, another iron chelator clioquinol, exhibited neuroprotection following both MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) administration (Kaur et al., 2003) and in a transgenic a-Syn mouse model (Finkelstein et al., 2016) .
In our effort to develop multifunctional symptomatic and disease modifying drugs for PD, we report here the pharmacological characterization of a novel, multifunctional compound, termed D-607 ( Fig. 1 ) based on our hybrid drug design template (Das et al., 2017; Dutta et al., 2004) . In this molecule, a D 2 /D 3 agonist moiety is linked to a bipyridyl moiety, a known iron-chelating agent that has preferential affinity for Fe 2þ (Breuer et al., 1995; Cabantchik et al., 1996; Romeo et al., 2001) . The presence of a bipyridyl fragment is highly significant due to the fact that the ratio of Fe 3þ :Fe 2þ from 2:1 in normal subjects is shifted to 1:2 in PD patients (Weinreb et al., 2013) . Iron in the Fe 2þ state can potentially participate in the Fenton reaction to generate reactive oxygen species (Rouault and Cooperman, 2006) . Thus, a Fe 2þ preferring chelator should provide greater beneficial effect against neurodegeneration. The lead molecule, D-607, not only exhibited potent in vivo activity in a PD animal model but also displayed neuroprotection effect in a cellular model which was attributed to preferential complexing with Fe 2þ (Das et al., 2017) . Moreover, the compound was efficacious in significantly reducing lipid peroxidation induced by Fe 2þ in vitro delineating its antioxidant property (Das et al., 2017) . Here, we provide a detailed biological characterization of D-607 to demonstrate its potent multifunctional neuroprotection properties both in vitro and in vivo. Our in vitro result indicates strong protection effect of D-607 in PC12 cells from toxicity associated with 6-OHDA, a cellular PD model. In a highly relevant in vivo experiment involving a validated PD Drosophila model that expresses a pathogenic, mutant variant of a-Syn protein in fly eyes, the test compound is shown to have significant protective activity. Moreover, in an in vivo study using the well-characterized MPTP administration mouse model of PD, the compound was found to be significantly neuroprotective under both sub-chronic and chronic administration of the toxin (Przedborski et al., 2000 (Przedborski et al., , 2004 . Additional mechanistic studies were carried out to support our neuroprotection data. In addition to symptomatic benefit, this multifunctional drug should also provide a degree of neuroprotection over the course of treatment, the latter endowing the compound with disease-modifying capabilities.
Materials and methods

Synthesis of D-607
D-607 ( Fig. 1 ) was synthesized by a multistep synthesis process as described in our recent publication (Das et al., 2017) .
Cell treatments with D-607
in the presence of 6-OHDA PC12 cells (ATCC ® CRL1721.1™, Manassas, VA, USA), a rat adrenal pheochromocytoma cell line, were cultured in T-75 flasks (Greiner Bio One, Frickenhausen, Germany) and maintained in RPMI 1640 medium supplemented with 10% heat-inactivated horse serum, 5%
fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37 C in 95% air/5% CO 2 . To assess the neuroprotective effects of the test compound, PC12 cells were pre-treated with different concentrations of D-607 for 1 h and then the drugcontaining media replaced with fresh culture media. Next, the cells were treated with 75 mM of 6-OHDA and finally incubated for another 24 h at 37 C in 5% CO 2 . The control cells were treated with above media containing 0.01% DMSO only.
Measurement of cell viability
To determine the neuroprotective effects of the test compound from 6-OHDA mediated cell death, a quantitative colorimetric MTT assay was performed. PC12 cells were plated at 17,000 cells/ well density in 100 mL media in 96 well plates for 24 h. Cells were treated with varying concentrations of D-607 for 1 h followed by treatment with 75 mM of 6-OHDA as above. After incubation for 24 h, 5 mg/mL MTT solution (prepared in 1X PBS) was added to the cells (to a final concentration of 0.5 mg/mL) and the plates were further incubated at 37 C in 95% air/5% CO 2 atmosphere for 3e4 h to produce dark blue formazan crystals. Afterwards, the plates were centrifuged at 450 g for 10 min and the supernatants were carefully removed. Formazan crystals were dissolved by adding 100 mL of methanol:DMSO (1:1) mixture to each well and shaking at 25 C for 30 min. Absorbance values were measured on a microplate reader (Biotek Epoch, Winooski, VT, USA) at 570 nm with background correction performed at 690 nm. Data from at least three experiments were analyzed using Graphpad software (Version 4, San Diego, CA, USA). Cell viability was defined as percentage reduction in absorbance compared to untreated controls.
Drosophila ebased studies
Fly stocks were maintained in standard cornmeal food at 25 C in incubators maintained at~60% humidity with diurnal cycle. For experiments, flies were crossed, raised and maintained at 30 C in standard cornmeal media. Once offspring eclosed from their pupal cases, they were switched to custom-made instant fly food (Genesee Scientific) containing either compound D-607 at a final concentration of 0.1 or 0.25 mg/mL (in ultra-pure water) or Rifampicin (Sigma-Aldrich) at 1 mg/mL (in DMSO) and maintained at 30 C. Vehicle control flies were maintained in the same type of food and the same conditions. At specific time points, fly heads were dissected for fluorescence imaging with an Olympus BX53 microscope equipped with a DP72 digital camera; fluorescence from each eye was quantified using the publicly available ImageJ software. Average retinal fluorescence for each treatment condition were calculated as previously described Tsou et al., 2015a; Yedlapudi et al., 2016) .
Native gels, western blotting and quantification
Post-fluorescence imaging, dissected fly heads were homogenized for use with the NativePAGE™ Novex ® Bis-Tris Gel System (Life Technologies), as outlined by the manufacturer. Briefly, fly heads were homogenized using a Dunce homogenizer in 4X Native sample buffer. Lysates were centrifuged at 20,000 Â g for 30 min at 4 C, the supernatant was loaded onto gradient 3e12% pre-cast native gels (BN1003BOX, Life Technologies) and proteins were electrophoresed in 1X light blue Cathode buffer containing 0.5% NativePAGE™ Cathode Additive (BN 2002, Life Technologies) . Proteins were transferred onto a PVDF membrane and detected using anti-a-Syn antibody (SC-7011-R, Santa Cruz, Biotechnology; 1:500). Anti-tubulin antibody (Sigma Aldrich; 1:5000) was used as loading control. Peroxidase conjugated secondary antibodies: goat antirabbit and goat anti-mouse (Jackson Immunoresearch; 1:5000) were used for visualization using chemiluminiscence (Clarity™ Western ECL Substrate, Bio-Rad) on a CCD-equipped VersaDoc 5000 MP system (Bio-Rad). The signals from the western blots were quantified using the Quantity One Software (Bio-Rad) with global noise reduction and using non-saturated blots as described before (Blount et al., 2012 (Blount et al., , 2014 Tsou et al., 2015b; Winborn et al., 2008) .
2.6. In vivo MPTP neuroprotection studies 2.6.1. Sub-chronic administration 12-week old male C57BL/6 mice (Jackson Labs, Bar Harbor, ME) used in this study were housed according to standard animal care protocols, kept on a 12 h light/dark cycle, and maintained in a pathogen-free environment in the Buck Institute vivarium. All experiments were approved by local IACUC review and conducted according to current NIH policies on the use of animals in research. The compound D-607 was diluted to a final dose of 5 mg/kg dissolved in saline and administered intraperitoneally (i.p.) to mice once daily for 5 days; control animals received saline vehicle. On day 4, mice were co i.p.-injected with either saline vehicle or 20 mg/kg MPTP (Sigma-Aldrich), administered 12 h apart. D-607 or vehicle was administered 30 min before each MPTP injection (Joyce et al., 2003) .
Chronic administration
12-week old male C57BL/6 mice (Jackson Labs, Bar Harbor, ME) were used in this study. The test compound D-607 was diluted to a final dose of 5 mg/kg dissolved in saline and administered intraperitoneally (i.p.) to mice once daily for 8 days while control animals received saline vehicle only. On day 4, mice were co i.p.-injected with either saline vehicle or 20 mg/kg MPTP (SigmaAldrich), administered 24 h apart for five more days. D-607 or vehicle was administered 30 min before each MPTP injection.
HPLC assay of striatal dopamine levels
A subset of mice (n ¼ 4 per condition) were used for analysis of levels of striatal DA. Dissected striata (harvested 24 h after the final MPTP injection) were sonicated and centrifuged in chilled 0.1 M perchloric acid (PCA, 100 mL/mg tissue). Supernatants were taken for measurements of dopamine by HPLC as described previously (Beal et al., 1990 (Beal et al., , 1992 . Briefly, 15 mL supernatant was isocratically 
Stereological assessment of DAergic SNpc cell numbers
A subset of mice (n ¼ 8 per condition) were subjected to cardiac perfusion with PBS followed by 4% paraformaldehyde at day 7 following the final MPTP injection. Brains were removed, dehydrated in 30% sucrose, and sectioned at 20 mm. Immunohistochemistry was performed using antibody against tyrosine hydroxylase (1:1000 TH, Chemicon, Temecula, CA) followed by biotin-labeled secondary antibody and development using DAB (Vector Labs, Burlingame, CA) to immunostain dopaminergic neurons. TH-positive cells in the SNpc were counted stereologically using the optical fractionator method (Kaur et al., 2003) . Sections were cut at a 40 mm thickness, and every 4th section was counted using a grid of 100 Â 100 mm. TH staining was verified by Nissl staining (Pilati et al., 2008) .
2.9. Analysis of in vitro mitochondrial membrane potential by JC-1 staining PC12 cells were cultured in 96-well black plates in 100 mL of RPMI-1640 media in a CO 2 incubator overnight at 37 C. The cells were pretreated with different concentrations of D-607 (0.1, 1, 5, 10, 20 and 30 mM) for 1 h, following which media containing the compound was removed and the cells were treated with 75 mM of 6-OHDA for another 24 h. At the end of the experiment, JC-1 at a concentration of 2 mg/mL was added to the cells and incubated for 2 h in a CO 2 incubator at 37 C. The cells were washed twice with serum-free media to eliminate background fluorescence. Finally, 100 mL of serum free media was added to the cells and the fluorescence was measured using the Synergy Hybrid H1 fluorescence microplate reader (BioTek). JC-1 J-aggregates display fluorescence with excitation and emission at 550 nm and 600 nm while JC-1 monomers exhibit excitation and emission at 485 nm and 535 nm, respectively. The ratio of fluorescence intensities of J-aggregates to monomers (Red/Green) was used as an indicator for mitochondrial health (Szelechowski et al., 2014) .
2.10. JC-1 staining image by fluorescence microscopy PC12 cells were cultured in 48-well plates in 500 mL of RPMI-1640 media in a CO 2 incubator overnight at 37 C. The cells were pretreated with different concentrations of D-607 for 1 h followed by treatment with 75 mM of 6-OHDA for another 24 h according to the procedure described above. Then the cells were treated with JC-1 at a concentration of 2 mg/mL and incubated for 2 h, after which they were washed twice with serum-free media to eliminate background fluorescence. Finally, 300 mL of serum free media was added to the cells. Healthy cells with predominant JC-1 J-aggregates were detected with fluorescence settings designed to detect rhodamine (Texas Red filter) and apoptotic or unhealthy cells with mainly JC-1 monomers were detected with settings designed to detect FITC (GFP filter). Images were taken at 20Â magnification with EVOS™ FL Cell Imaging System (Advanced Microscopy Group, USA). Representative images from two different sets of experiments were taken.
Western blots of hypoxia-inducible factor (HIF) levels
PC12 cells in RPMI 1640 media were plated at 5.5 Â 10 5 cells/ well density in 6-well plates and they were allowed to adhere for 24 h. Then the cells were treated with varying concentrations of D-607 for 1 h after which the media containing drug was removed followed by incubation in fresh RPMI media for another 24 h. Cells were washed twice in ice-cold PBS and lysed in RIPA buffer for 30 min at 4 C. A total of 40 mg protein was separated on 8% SDSpolyacrylamide gels (SDS-PAGE) and transferred to the polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). The membrane was blocked with 5% (w/v) nonfat dry milk in TBS-T for 1 h at room temperature. Afterwards, the blocked membrane was incubated overnight at 4 C with antieHIFe1a antibody (Novus Biologicals, USA; catalog # NB100e105SS) at a dilution of 1:500 in 5% (w/v) nonfat dry milk in TBS-T. Blots were washed three times in TBS-T and incubated for 1 h at room temperature with HRP-conjugated anti-mouse secondary antibody (1:5000) in 5% (w/v) nonfat dry milk in TBS-T. The image was visualized using ECL-Plus reagent (PerkineElmer, Waltham, MA, USA) and ImageQuant LAS 4000 imager (GE Healthcare Biosciences, Pittsburgh, PA, USA). Densitometric analysis was performed using ImageJ software.
Statistics
Two-tailed Student t-tests or ANOVA with Tukey's post-hoc correction were used to assess retinal eye degeneration in treatment versus control groups, as appropriate, and as indicated in figure legends. For multiple groups distributed normally, statistical significance was determined using one-way ANOVA following Tukey's multiple comparison as well as Dunnett's post hoc test. In all cases, p < 0.05 was considered as statistically significant.
Results
Cell culture-based neuroprotection study
We first explored the neuroprotective effect of D-607 in vitro in PC12 cells against 6-OHDA-induced cytotoxicity. Treatment of PC12 cells with 6-OHDA for 24 h resulted in significant, dosedependent neurotoxicity as indicated by a significant decrease (~50%) in cells exposed to 75 mM 6-OHDA; this concentration was used in subsequent in vitro experiments (also see Fig. 5a , Shah et al., 2014) . The potential neuroprotective effect of D-607 on 6-OHDAinduced toxicity was evaluated following pre-treatment with the drug. When cells were pre-treated with D-607 for 1 h prior to exposure to 6-OHDA treatment for 24 h, this resulted in dosedependent protection against neurotoxicity. The highest protective effect was obtained at a concentration of 5 mM where cell survival was increased by~60% compared to 6-OHDA (75 mM) treatment alone (Fig. 2 and Supl. Fig. 1 ).
a-Syn-dependent toxicity in Drosophila
Compound D-607 was next examined for its ability to suppress neurotoxicity associated with a disease-causing variant of a-Syn in the fruit fly Drosophila melanogaster. Expression of both wild type and mutant variants of a-Syn in the fruit fly leads to age-dependent neurotoxicity Feany and Bender, 2000) . We utilized a sensitive technique in order to detect and track degeneration in fly eyes when a-Syn is expressed in them. This method reports retinal degeneration by making use of membrane-targeted GFP, whose fluorescence diminishes as internal structures deteriorate and collapse Tsou et al., 2015a; Yedlapudi et al., 2016) .
Expression of a-Syn in fly eyes is toxic. As shown in Fig. 3A , expression of a mutated version of a-Syn (mutation A30P, linked to human disease (Kruger et al., 1998) ;) in fly eyes causes loss of overall GFP fluorescence and increased mosaicism when a-Syn is expressed in them. Quantification of overall eye fluorescence highlights these findings. As reported in our recent publication, we used rifampicin, which has been shown to suppress a-Syn toxicity in cell models (Bi et al., 2013; Li et al., 2004) , as a positive reference for suppression of a-Syn-dependent retinal toxicity (Yedlapudi et al., 2016) . Flies were reared in media that did not contain the drug until the day when they eclosed from the pupal case. At that time, adults were switched to media containing rifampicin or its vehicle control (DMSO) for 21 days. As shown in Fig. 3B , flies fed rifampicin for 21 days showed increased GFP fluorescence significantly compared with flies that were fed the vehicle control, indicative of neuroprotection from a-Syn.
We then proceeded to examine the ability of D-607 to suppress toxicity from a-Syn through this parameter. As with rifampicin, flies were reared on media without the drug, and were switched to media containing D-607 or its vehicle (ultra-pure water) after they eclosed from the pupal case. Flies that were fed the iron chelator D-607 showed a dose-dependent increase in GFP fluorescence Fig. 2 . Dose-dependent effect of D-607 on cell viability of PC12 cells from toxicity induced by 75 mM 6-OHDA. PC12 cells were pre-treated with varying concentrations of D-607 for 1 h after which the media was replaced with fresh culture media followed by treatment with 75 mM 6-OHDA for another 24 h. The values shown are the mean ± SD of at least three independent experiments performed in four to six replicates. One way ANOVA analysis F (8, 62) ¼ 160.8, p < 0.0001. ANOVA was followed by Tukey's multiple comparison post hoc test (****p < 0.0001 compared to 6-OHDA only and ####p < 0.0001 compared to control). compared with their vehicle-treated siblings (Fig. 3C) . Collectively, these data indicate a protective role from D-607 in this synucleinopathy model. In order to evaluate a possible role of iron chelating effect in reduction of a-Syn induced toxicity, we tested compound D-636, a close analog of D-607. D-636 is a potent dopamine agonist, but unlike D-607, it does not have iron chelating property. As shown in Supl. Fig. 2 , D-636 was unable to produce significant reduction of toxicity at the same dose and time point as to D-607. This suggests a role from iron chelation in enhancement of protection from toxicity of a-Syn by D-607.
To obtain additional insight into the manner in which compound D-607 reduces a-Syn neurotoxicity in the Drosophila model, we utilized native gel analyses to examine levels of various a-Syn species. Representative results from these assays are shown in Fig. 4 . As highlighted in Fig. 4 , left portion, a-Syn migrates as a monomer and as multimeric species in native gels. Some a-Syn bands and smears are visible in lighter exposures, whereas longer exposures are required to observe others. We show three different exposures from one of the experiments. To compare the monomeric and multimeric species of a-Syn in each lane (Fig. 4 , right portion), we quantified the monomeric band (arrow), the entire multimeric smear (bracket), and the total a-Syn signal (monomer þ multimer) for each band. Then, we determined the portion of monomeric and multimeric a-Syn for each lane, based on total a-Syn, and normalized those results to the monomeric and multimeric values for the vehicle-treated control. It is these results that are shown as histograms in Fig. 4 . Treatment of flies with D-607 for 21 days at 0.1 or 0.25 mg/mL led to a mild, but statistically significant, increase in monomeric species concomitant with reduction in multimeric or aggregated aSyn forms compared to vehicle-only control (Fig. 4) . This increase in monomeric a-Syn species was found to coincide with reductions in toxicity from this protein (Fig. 3) , supporting the notion that the compound protects against a-Syn-dependent degeneration in fly eyes via decreased levels in aggregated a-Syn species.
3.3. Neuroprotective effects of D-607 under conditions of systemic sub-chronic and chronic MPTP treatment in mouse 3.3.1. D-607 protects against MPTP-induced depletion of striatal DA content during sub-chronic administration Effect of pre-treatment with 5 mg/kg D-607 for three days followed by two days co-treatment with MPTP (20 mg/kg, 12 h apart) resulted in significant protection against losses in DA levels compared to control MPTP alone. Specifically, while treatment with MPTP alone at a dose 20 mg/kg, 12 h apart resulted in a 75% depletion in striatal DA levels compared to controls, treatment with 5 mg/kg D-607 significantly reduced this striatal DA depletion (~28% reduction in DA loss versus MPTP treatment alone (p < 0.001, Fig. 5a ).
D-607 protects against MPTP-induced depletion of striatal DA content following chronic administration
Effects of pre-treatment of 5 mg/kg D-607 for 3 days followed by 5 days co-treatment with MPTP (20 mg/kg, 24 h apart) resulted in significant protection against losses in striatal DA levels. Specifically, treatment with MPTP alone resulted in 80% depletion in striatal DA levels compared to controls, while pre-treatment with D-607 reversed this loss by~32% (Fig. 6a) .
3.3.3. D-607 protects against MPTP induced SNpc DAergic cell loss during sub-chronic administration Treatment with MPTP using the above dosage regime for subchronic administration resulted in a significant loss (39%) of DAergic SNpc neurons compared to untreated controls. Pretreatment with 5 mg/kg of D-607 conferred a significant reduction (22%) against DAergic SNpc neuronal loss compared to MPTPtreated group (p < 0.001, Fig. 5b ).
D-607 protects against MPTP-induced SNpc DAergic cell loss during chronic administration
Treatment with MPTP under chronic administration regimen led to loss of 40% DAergic SNpc neurons compared to untreated control while both pre-treatment and co-treatment with 5 mg/kg D-607 resulted in significant reduction (21%) of this cell loss (Fig. 6b) .
Mitochondria as a therapeutic target for PD
We next analyzed the ability of D-607 to modulate downstream effects on mitochondrial dysfunction. For these studies, we utilized JC-1 staining in our 6-OHDA cellular PD model as an indicator of mitochondrial health (Wagner et al., 2008) . The staining was done by lipophilic fluorescent cationic dye JC-1 as an indicator of mitochondrial membrane potential (MMP). JC-1 forms red fluorescent Jaggregates when MMP is maintained or restored, while it forms green fluorescent monomers in the presence of decreases in MMP. Pre-treatment with D-607 led to an increase in the red/green ratio in a dose-dependent manner when compared to 6-OHDA treatment alone. D-607 alone did not have an observable effect on the mitochondrial membrane potential except at a higher dosage (30 mM) (Fig. 7a) . However, treatment with D-607 was found to increase mitochondrial membrane potential compared to 6-OHDA alone in a concentration-dependent manner. The most significant increase was shown in a concentration range of 5e30 mM (Fig. 7b) .
These data were further corroborated via fluorescent microscopy demonstrating a decrease in numbers of J-aggregates (Fig. 8) ; however, D-607 was able to reverse the effects caused by 6-OHDA as evidenced by increases in numbers of J-aggregates.
Inhibition of prolyl hydroxylase (PHD) and up-regulation of HIF by D-607
To further probe into possible mechanisms involved in neuroprotection elicited by D-607, we carried out a well characterized cell based assay evaluating effects of drug on HIF-1a levels as a surrogate for inhibition of iron-dependent prolyl hydroxylase activity (Callapina et al., 2005; Yeoh et al., 2013) . It has been demonstrated that elevation of HIF-1a level as a result of inhibition of PHD prevents neuronal death and provides neuroprotection (Lee et al., 2009; Siddiq et al., 2005) . PC12 cells were treated with D-607 for 1 h following the same protocol we employed in our in vitro neuroprotection experiments. As shown in Fig. 9 , we observe a significant increase in HIF-1a levels following treatment of PC12 cells with D-607.
Discussion
We recently demonstrated the development of bipyridinebased, hybrid D 2 /D 3 ligands that exhibit potent agonist efficacy in GTPgS binding functional assays. Our previous iron binding study revealed far higher specificity for complex formation of D-607 with Fe(II) compared to Fe(III). This study also indicated a neuroprotective effect of D-607 in neuronal PC12 cells against iron (II)-induced cell death (Das et al., 2017) . The fact that compound D-607 was able to rescue these cells strongly indicated the ability of selective intracellular complexation of Fe(II) by the compound to reduce oxidative stress. This was further validated in a cell-based lipid peroxidation assay where pre-treatment with the compound was found to significantly reduce iron (II) induced lipid peroxidation. Our results also demonstrated D-607 to be much more neuroprotective in this experimental model versus pramipexole and a 8-hydroxyquinoline-derived Fe(III) preferring dopamine agonist, thereby, reflecting contribution of the bipyridyl moiety in enhanced neuroprotection (Das et al., 2017) .
In an in vitro 6-OHDA PD model, pre-treatment with different doses of D-607 was able to restore cell viability to almost control levels (Fig. 2) . 6-OHDA is a widely-used toxin that mimics the generation of oxidative stress observed in PD which induces neurotoxicity via its auto-oxidation and subsequent hydrogen peroxide generation (Blum et al., 2000; Soto-Otero et al., 2000) . It is interesting and worth mentioning that only a single hour pretreatment of D-607 was sufficient to protect cells from this neurotoxin.
We next assessed the in vivo neuroprotection potential of this compound in a proteotoxicity Drosophila model in which mutant pathogenic a-Syn protein is expressed specifically in fly eyes to produce detectable and quantifiable toxicity. Drosophila has a proven track record as a model for human neurodegenerative diseases (Bonini and Fortini, 2003; Jaiswal et al., 2012) . The fruit fly is a complex living organism with an intricate nervous system whose molecular pathways are closely related to human. We previously reported a method to examine retinal degeneration in this model . This GFP-based technique is sufficiently sensitive that it can report degeneration even before it is consistently and easily observed through histology or by observing external eye structures. We have successfully used this technique to describe retinal degeneration caused by various toxic neurodegenerative disease proteins and as a means to identify modifiers for them Tsou et al., 2015a; Yedlapudi et al., 2016) .
Our results showed that the compound rifampicin significantly protects fly eyes from mutant a-Syn-based toxicity compared to untreated control in a dose-dependent manner (Fig. 3 , Panels B, C). This confirms previous results on the protective effect of rifampicin on neurotoxicity associated with a-Syn (Li et al., 2004) . Treatment with D-607 at two different doses was effective. The effect was dose dependent as the 0.25 mg/mL concentration was more efficacious in this regard (Fig. 3 , Panel C). Our results also indicate disruption of the formation of toxic aggregates in this model in the presence of D-607. To investigate the mechanism of neuroprotection, we carried out western blot-based analyses of the ratio of a-Syn species in the absence or presence of drug. Reductions in aggregate formation were found coincident with reductions in neurodegeneration in this model (Fig. 4) . Interestingly, a non-iron chelating dopamine agonist D-636, a close analog of D-607, did not exhibit significant protection against a-Syn toxicity under the same experimental condition (Supl. Fig. 2 ). This indicates a possible role of iron chelation in protection from toxicity. To further establish the neuroprotective effects of D-607 in vivo, we carried out additional studies utilizing the well-characterized MPTP administration mouse model. Systemic administration of MPTP produces selective destruction of DAergic SNpc neurons in both primates and rodents, resulting in an acute Parkinsonism phenotype (Lee et al., 2009; Przedborski et al., 2004) . MPTP has been suggested to exert its neurotoxic effect via selective inhibition of mitochondrial complex I activity, resulting in both a reduction in ATP synthesis and accumulation of reactive oxygen species. MPTP therefore reproduces many of the hallmarks of PD-associated neurodegeneration. Results from these studies demonstrated D-607 pre-treatment prevents losses in striatal dopamine levels and DAergic SNpc neurons elicited by either sub-chronic or chronic MPTP administration. Specifically, neurochemical striatal analysis showed significant protection (>28%) against MPTP-mediated losses in DA content in mice pretreated with D-607 following subchronic MPTP administration compared to MPTP-alone. Similarly, significant protection (>22%) against striatal DAergic cell loss as assessed by sterological cell counting was observed in the D-607 pre-treatment group compared to MPTP treatment alone (Fig. 5bec) . In the case of chronic administration of MPTP, a robust neuroprotective effect was observed (>39%) in both striatal DA loss (Fig. 6a) and reductions in DAergic SN cell numbers (21%, Fig. 6bec) . As found by the other investigators, we do not see a significant impact from the treatment with D-607 alone on the level of DA and TH cell counts (Joyce et al., 2003; Zou et al., 2000) . D-607 did not influence the metabolic conversion of MPTP to MPP þ demonstrating that the conferred neuroprotection is not due to alterations in production of MPP þ by the drug (Supl. Fig. 3 ).
Mechanisms associated with the neuroprotective effects of D-607 from in vitro 6-OHDA and in vivo MPTP neurotoxicity may be partly explained by its ability to protect against oxidatively-induced alterations in mitochondrial dysfunction (Smiley et al., 1991; Szelechowski et al., 2014) . For these studies, we employed the lipophilic fluorescent cationic dye JC-1 as an indicator of MMP. As mentioned above, maintenance or restoration of MMP is indicated by red fluorescence from J-aggregates, while it forms green fluorescent monomers when MMP decreases. Our results indicate that D-607 is able to protect against losses in MMP induced by 6-OHDA (Fig. 7b) . Both 6-OHDA and MPTP neurotoxicity are known to impair mitochondrial activity.
Inhibition of iron-dependent PHD activity, by preventing the ubiquitination and subsequent degradation of HIF-1a by the proteasome has been demonstrated to be neuroprotective against MPTP toxicity (Lee et al., 2009; Rajagopalan et al., 2016) . Interestingly, deferoxamine, an iron chelator, has also been shown to upregulate HIF-1a (Guo et al., 2016) . We observed a clear induction of HIF-1a level by D-607 in PC12 cells from concentration of drug as low as 100 nM to a higher concentration of 5 mM (Fig. 9 ). This result is in line with the known inhibitory activity of bipyridyl against PHD activity (Hales and Beattie, 1993; Ivan et al., 2002) . The ability of D-607, acting in its capacity as an iron chelator, may also provide neuroprotection via its ability to inhibit PHD and up-regulate HIF1a levels. In summary, the absence of a disease-modifying drug for PD makes the development of multifunctional neuroprotective agents an important therapeutic strategy. To address this unmet medical need and the emerging role of redox-reactive iron (II) in PD, we previously developed a novel Fe 2þ preferring DA agonist chelator, D-607. Here we show that the compound is neuroprotective in a cellular 6-OHDA induced neurotoxin PD model. In a unique in vivo fruit fly Drosophila melanogaster model specifically expressing a disease-causing variant of a-Syn protein in fly eyes, D-607 was found to suppress retinal degeneration coinciding with reductions in toxic aÀSyn aggregate formation. Finally, in a well-known mouse MPTP PD animal model, D-607 was shown to confer significant neuroprotection against MPTP toxicity both in terms of losses in striatal DA levels and DAergic SNpc cell numbers following both sub-chronic and chronic MPTP administrations. Finally, we provide some possible mechanistic insights towards delineating the observed neuroprotective properties of the drug. Results from these studies, therefore, underpin the notion that a multifunctional drug like D-607 has the potential not only to ameliorate motor dysfunction in PD patients (Das et al., 2017) , but also to modify disease progression by protecting DA neurons from neurotoxic insults.
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